Provided by Tiger Fintech (Singapore) Pte. Ltd.

AbCellera Biologics

2.52
+0.12005.00%
Pre-market: 2.570.0500+1.98%07:06 EDT
Volume:4.45M
Turnover:11.23M
Market Cap:750.93M
PE:-4.55
High:2.60
Open:2.45
Low:2.45
Close:2.40
Loading ...

Abcellera Biologics Inc: Qtrly Shr Loss $0.12

THOMSON REUTERS
·
28 Feb

AbCellera Reports Full Year 2024 Business Results

Business Wire
·
28 Feb

AbCellera Biologics Changes COO's Title to Technology Chief

MT Newswires Live
·
19 Feb

AbCellera COO transitions to Chief Technology Officer

TIPRANKS
·
19 Feb

One AbCellera Biologics Insider Raised Their Stake In The Previous Year

Simply Wall St.
·
18 Feb

AbCellera to Participate at Upcoming Investor Conferences in March

Business Wire
·
12 Feb

AbCellera Biologics On Track For Largest Percent Increase Since August 2022 -- Data Talk

Dow Jones
·
23 Jan

3 Promising US Penny Stocks With Market Caps Under $900M

Simply Wall St.
·
22 Jan

Press Release: AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Dow Jones
·
22 Jan

AbCellera Biologics Inc. (NASDAQ:ABCL) most popular amongst individual investors who own 36% of the shares, institutions hold 29%

Simply Wall St.
·
20 Jan

AbCellera expands collaboration with AbbVie

TipRanks
·
14 Jan

AbCellera Expands Discovery Partnership With AbbVie

Dow Jones
·
13 Jan

Abcellera Biologics: to GET Upfront, Research Payments, Is Eligible to GET Downstream Milestone Payments & Tiered Royalty Payments on Net Sale

THOMSON REUTERS
·
13 Jan

Abcellera Expands Collaboration With Abbvie to Develop Novel T-Cell Engagers for Oncology

THOMSON REUTERS
·
13 Jan

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Business Wire
·
13 Jan

KeyBanc Cuts Price Target on AbCellera Biologics to $4 From $5, Keeps Overweight Rating

MT Newswires Live
·
08 Jan